RO7567132 (FAP-LTBR) is a novel bispecific antibody that binds and agonizes LTBR bivalently while binds and antagonizes FAP monovalently, thereby limiting the activation of LTBR to the tumor microenvironment, inducing the formation of local tertiary lymphoid structures (TLS), and reducing systemic toxicity. Its mouse alternative can inhibit breast cancer growth, and the effect is better when combined with atezolizumab. In the mouse colorectal cancer model, it can also enhance immune cell infiltration and TLS-like structure formation.